

UNITED STATES INTERNATIONAL TRADE COMMISSION
Washington, DC 20436

**MEMORANDUM ON PROPOSED TARIFF LEGISLATION
of the 109th Congress ¹**

[Date approved: June 7, 2006]²

Bill No. and sponsor: S. 1487 (Mr. Rick Santorum of Pennsylvania).

Proponent name, location: Bayer MaterialScience LLC, Pittsburgh, PA.

Other bills on product (109th Congress only): None.

Nature of bill: Temporary duty suspension through December 31, 2009.

Retroactive effect: None.

Suggested article description(s) for enactment (including appropriate HTS subheading(s)):

4-(4-[3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido]phenoxy)-N²-methylpyridine-2-carboxamide 4-methylbenzenesulfonate (Sorafenib tosylate) (CAS No. 4750207-59-1) (provided for in subheading 2933.39.41).

Check one: Same as that in bill as introduced.
 Different from that in bill as introduced (see Technical comments section).

Product information, including uses/applications and source(s) of imports:

The subject product is a bulk active ingredient that is used to formulate drugs to treat cancer and as a replacement for certain antiviral drugs. The subject chemical is imported from Germany.

Estimated effect on customs revenue:

HTS subheading: <u>2933.39.41</u>					
	2006	2007	2008	2009	2010
Col. 1-General rate of duty	6.5%	6.5%	6.5%	6.5%	6.5%
Estimated value <i>dutiable</i> imports	\$10,000	\$10,000	\$10,000	\$10,000	\$10,000
Customs revenue loss	\$650	\$650	\$650	\$650	\$650

Source of estimated dutiable import data: Industry estimates.

¹ Industry analyst preparing report: Robert Randall (202-205-3366); Tariff Affairs contact: David Michels (202-205-3440).

² Access to an electronic copy of this memorandum is available at http://usitc.gov/tata/hts/other/rel_doc/bill_reports/index.htm.

Contacts with domestic firms/organizations (including the proponent):

Name of firm/organization	Date contacted	Claim US makes same or competing product(s)?	Submission attached?	Opposition noted?
		(Yes/No)		
Bayer MaterialScience LLC (Proponent) Karen Niedermeyer, 412-777-2058	05/04/2006	No	No	No
Abbott Laboratories David Landside Fax: 202-466-8386	05/04/2006	No	No	No
Bristol-Myers Squibb David Warr Fax: 202-783-2308	05/04/2006	No	No	No
DuPont Helen McMahon Fax: 302-774-1398	05/04/2006	No	No	No
Endo Labs Camille Ali Jackson Fax: 610-558-9685	05/04/2006	No	No	No
Gilead Sciences Cheryl Myriad Fax: 650-522-5853	05/04/2006	No	No	No
Glaxo Welcome Sara Froelich Fax: 202-715-1001	05/04/2006	No	No	No
Interferon Sciences Samuel Ronel Fax: 732-249-6895	05/04/2006	No	No	No
Merck & Co. Thomas Bombelles Fax: 202-638-3670	05/04/2006	No	No	No
Niche Pharmaceuticals Steve Brandon Fax: 817-491-3533	05/04/2006	No	No	No
Novartis Tracy Haller Fax: 202-628-4763	05/04/2006	No	No	No
Noveon Tom Dirmyer Fax: 214-415-6001	05/04/2006	No	No	No
Pfizer Phillip Ellsworth Fax: 212309-5317 Katherine Bennett Fax: 202-347-2024	05/04/2006	No	No	No
Procter & Gamble Jim McCarthy Fax: 202-393-4606	05/04/2006	No	No	No
Schering-Plough Rob Lively Fax: 202-463-8809	05/04/2006	No	No	No
Watson Pharmaceuticals Sara Swee Fax: 909-270-1429	05/04/2006	No	No	No

Technical comments:³

The Commission suggests that the article description on page 1 of this report be used in the proposed new heading in order to provide the chemical name.

³ The Commission may express an opinion on the HTS classification of a product to facilitate consideration of the bill. However, by law, only the U.S. Customs Service is authorized to issue a binding ruling on this matter. The Commission believes that the U.S. Customs Service should be consulted prior to enactment of the bill.

109TH CONGRESS
1ST SESSION

S. 1487

To suspend temporarily the duty on Sorafenib.

IN THE SENATE OF THE UNITED STATES

JULY 26, 2005

Mr. SANTORUM introduced the following bill; which was read twice and referred to the Committee on Finance

A BILL

To suspend temporarily the duty on Sorafenib.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SORAFENIB.**

4 (a) IN GENERAL.—Subchapter II of chapter 99 of
5 the Harmonized Tariff Schedule of the United States is
6 amended by inserting in numerical sequence the following
7 new heading:

“	9902.09.04	Sorafenib tosylate (CAS No. 4750207-59-1) (provided for in subheading 2933.39.41) ..	Free	No change	No change	On or before 12/31/2009	”.
---	------------	--	------	-----------	-----------	-------------------------	----

8 (b) EFFECTIVE DATE.—The amendment made by
9 subsection (a) applies to goods entered, or withdrawn from

2

- 1 warehouse for consumption, on or after the 15th day after
- 2 the date of enactment of this Act.

○